

Date: August 11, 2016

To, Listing Department, Dept. of Corporate Services, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Fort, Mumbai: 400 001,

General Manager, National Stock Exchange of India Ltd., Exchange Plaza, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai: 400 051.

Dear Sir/Madam,

Ref .:-

Scrip Code - 532908 Scrip ID-SHARONBIO

Sub:- Outcome of the Board Meeting held on Thursday, August 11, 2016.

With the reference to the above captioned subject, we wish to intimate your esteemed exchanges that as decided in the Meeting of the Board of Directors of the Company held on today, i.e. Thursday, August 11, 2016, for which intimation was already given to you, the Board of Directors has:

- Approved and taken on record the Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2016 along with the Limited Review Report thereon.
- Finalized the appointment of Mr. Deep Shukla, Practicing Company Secretary as the Scrutinizer to oversee the e-voting process and voting done through physical ballot paper, in a fair and transparent manner;
- Adopted and Approved the Notice of forthcoming 27th Annual General Meeting to be held on Tuesday, 27th day of September, 2016, Director's Report and Corporate Governance Report for the financial year 2015-2016.
- Finalized the dates of the Book Closure for the forthcoming 27th Annual General Meeting from Tuesday, September 20, 2016 to Tuesday, September 27, 2016 [both days inclusive];
- Decided to convene 27th Annual General Meeting of the Members of the Company on Tuesday, 27th September, 2016 at Plot No. V/10, MIDC, Taloja, Dist. Raigad, Maharashtra 410 208 at 9.30 A.M.

Adm. Off.: 312. C Wing. BSEL Tech Park. Sector - 30(A), Vashi, Navi Mumbai - 400 705 Tel:: 91 22 - 67944000, Fax:: 91 22 - 67944001 www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



Further, we wish to inform BSE and NSE, that in terms of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management & Administration) Amendment Rules 2015, the Company will provide its Shareholders the facility to exercise their vote for transacting the items of ordinary and special businesses, if any at the ensuing 27th Annual General Meeting (AGM) to be held on Tuesday, September 27, 2016, by electronic means, including remote e-voting. The Company would be availing e-voting services of Central Depository Services (India) Limited (CDSL) / National Securities Depository Limited (NSDL). Further pursuant to the Companies (Management & Administration) Amendment Rules 2015, the Company has fixed September 20, 2016 as the Cutoff date for determining the eligibility to vote by electronic means or in the ensuing 27th Annual General Meeting.

Kindly find the same in order and acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

For Sharon Bio-Medicine Limited

Mrs. Savita Gowda Managing Director DIN: 00042957

Encl: a/a

Adm. Off.: 312. C Wing. BSEL Tech Park. Sector - 30(A). Vashi, Navi Mumbai - 400 705 Tel: 91 22 - 67944000, Fax: 91 22 - 67944001 www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships





STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2016.

(₹ in Lacs)

(< In Lacs				
SR. NO.	PARTICULARS	3 Months Ended 30/06/2016	3 Months Ended 30/06/2015	Year Ended 31/03/2016
		(Un-Audited)	Audited	Audited (9 M)
1	Total Income from Operations (net)	3,783.26	14,195.82	25,345.48
2	Net Profit/(Loss) for the period			
	(before Tax, Exceptional and/or Extraordinary items)	(15,639.30)	(4,883.70)	(21,788.61)
3	Net Profit/(Loss) for the period before Tax			
	(after Exceptional and/or Extraordinary items)	(17,938.22)	(8,708.94)	(28,923.82)
4	Net Profit/(Loss) for the period after Tax			
	(after Exceptional and/or Extraordinary items)	(17,938.22)	(8,242.58)	(29,920.39)
5	Total Comprehensive Income for the period			
	[Comprising Profit/(Loss) for the period (after tax) and			
	other Comprehensive Income (after tax)	(17,938.22)	(8,242.58)	(29,920.39)
6	Paid-up Equity Share Capital (Face value of Rs.2/- each)	2,378.71	2,378.71	2,378.71
7	Reserves (excluding Revaluation Reserves) as shown in			
	the Audited Balance Sheet of the previous Year			(21,899.66)
8	Earnings Per Share (of Rs.2/- each)			
	(for continuing and discontinued operations) (not annualised)			
	a) Basic (in Rs.)	(15.08)	(6.93)	(25.16)
	b) Diluted (in Rs.)	(14.74)	(6.77)	(24.59)

Notes:

- 1) The above results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 11, 2016.
- 2) The Statutory Auditors of the Company has carried out the Limited Review of the above standalone results.
- 3) The above is an extract of the detailed format of the Standalone Financial Results for the quarter ended June 30, 2016 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange website, www.nseindia.com and www.bseindia.com, and on the Company's website www.sharonbio.com.

For Sharon Bio-Medicine Ltd.

SD/-

Place : Mumbai. Savita Gowda
Date : 11.08.2016 Managing Director.

REGISTERED OFFICE & WORKS: W-34 & 34/1, MIDC, Taloja, Dist.Raigad, Maharashtra (India).

CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai – 400 703.

E-mail: investor_complaints@sharonbio.com, Website: www.sharonbio.com